Screener
Xenon Pharmaceuticals XENE Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total operating expenses | 123,155 | 94,229 | 235,483 | 174,467 |
| Loss from operations | (123,155) | (94,229) | (235,483) | (166,967) |
| Other income: | ||||
| Interest income | 12,145 | 7,199 | 19,052 | 15,282 |
| Foreign exchange gain (loss) | (311) | 1,698 | 237 | 1,733 |
| Total other income | 11,834 | 8,897 | 19,289 | 17,015 |
| Loss before income taxes | (111,321) | (85,332) | (216,194) | (149,952) |
| Income tax recovery | 585 | 626 | 3,156 | 199 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's interest income?
- Xenon Pharmaceuticals (XENE) reported interest income of $12.15M in Q2 2026.
- How has Xenon Pharmaceuticals's interest income changed year-over-year?
- Xenon Pharmaceuticals's interest income increased by 68.7% year-over-year, from $7.2M to $12.15M.
- What is the long-term trend for Xenon Pharmaceuticals's interest income?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's interest income has grown at a 175.5% compound annual growth rate (CAGR), from $466K to $26.83M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Xenon Pharmaceuticals's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude